Skip to content

Comparative Analysis of Hemodynamic Effects of Remimazolam and Propofol Combined with Esketamine in Colonoscopic Procedures in the Elderly.

Bo-Ran Deng, Yang Zhang, Zi-Feng Xie, Ding-Ding Wang, Tao Zeng, Dong-Bo Zhang, Li Huang, Qi-Yan Wang, Tu Shen, Qiao-Ling Wu

Drug design, development and therapy January 1, 2024 DOI: 10.2147/DDDT.S490179 via PubMed

Summary

AI-generated from the abstract

In elderly patients undergoing painless colonoscopies, a combination of remimazolam and esketamine causes fewer drops in blood pressure and other hemodynamic complications than propofol plus esketamine. In a randomized trial with 754 patients, hypotension occurred in 9.78% of those given remimazolam-esketamine versus 23.57% in the propofol-esketamine group. The remimazolam group also had lower rates of sinus tachycardia, sinus bradycardia, and less need for blood-pressure-supporting drugs. Both sedative regimens achieved 100% sedation success, but the remimazolam combination led to a longer time to fall asleep yet faster recovery, along with less respiratory depression and injection pain. The findings indicate remimazolam with esketamine provides superior hemodynamic stability and safety for this population.

Study at a glance

Characteristics Randomized controlled trial Peer reviewed
Sample size 754
Population Elderly patients undergoing painless colonoscopies
Interventions Remimazolam-esketamine Propofol-esketamine
Dose 0.15 mg/kg of remimazolam and 0.3 mg/kg of esketamine; 1.5 mg/kg of propofol with 0.3 mg/kg of esketamine
Topics Esketamine
Keywords Elderly patients Hemodynamic effects Remimazolam Colonoscopy sedation
Citations 18
Key finding Remimazolam combined with esketamine resulted in significantly lower incidence of hypotension (9.78%) compared to propofol combined with esketamine (23.57%) in elderly patients undergoing painless colonoscopies.

Abstract

The debate continues over the differential impact of remimazolam vs propofol on hemodynamic stability. This study aims to elucidate the effects of a combination of remimazolam and esketamine vs propofol and esketamine on hemodynamic parameters in elderly patients undergoing painless colonoscopies. We conducted a randomized controlled trial involving 754 patients, divided equally between two treatment groups. The remimazolam-esketamine group (RE group) received 0.15 mg/kg of remimazolam and 0.3 mg/kg of esketamine. Conversely, the propofol-esketamine group (PE group) was administered 1.5 mg/kg of propofol with 0.3 mg/kg of esketamine. Primary outcomes focused on the incidence of hypotension. Secondary outcomes assessed were other hemodynamic adverse events, intraoperative blood pressure and heart rate fluctuations, usage of vasoactive agents, sedation efficacy, and additional adverse reactions. Hypotension occurred significantly less frequently in the RE group (9.78%, 95% confidence interval[CI]: 6.67-12.87%) compared to the PE group (23.57%, 95% CI: 21.22-30.52%), P<0.001. The RE group also showed lower incidences of sinus tachycardia, sinus bradycardia, and required less support from vasoactive agents (P<0.001). Additionally, the RE group experienced smaller fluctuations in blood pressure and heart rate (P<0.05). Both groups achieved a 100% sedation success rate. Notably, the RE group had a longer induction period but a quicker recovery time (P<0.001), and lower rates of respiratory depression (P=0.006) and injection pain (P<0.001). Remimazolam combined with esketamine offers superior hemodynamic stability and significantly reduces adverse event rates compared to propofol plus esketamine in elderly patients undergoing painless colonoscopies, while maintaining effective sedation.

Explore topics

Comments

No comments yet.

Log in to comment